Norwegian National Air Ambulance Services Choose Danish Blood/IV Fluid Warmer, ̊M Warmer System ( ̊MEQU)

Norwegian National Air Ambulance Services

 

˚MEQU, an innovative MedTech company from Denmark, is pleased to announce that it has won a public tender to provide portable blood and IV-fluid warming devices (˚M Warmer System) to Norwegian National Air Ambulance Services (Luftambulansetjenesten HF). 

Norwegian National Air Ambulance Services is responsible for all air ambulances (both fixed-wing and helicopters) and acute cars located at 13 bases throughout the country and is one of the most innovative and advanced HEMS (helicopter emergency medical services) programs in the world. The ˚M Warmer System was the only device meeting all mandatory requirements and was chosen due to its high quality – small size and light weight, heating capacity, and not least user-friendliness.

Prehospital fluid resuscitation is known to increase the survival rate of trauma patients. For this reason, carrying blood products onboard aircraft has been initiated by major European HEMS in recent years despite its complex and costly process in terms of blood supply and staff training. Moreover, aircraft should be equipped with a blood/IV fluid warmer as all fluids should be warmed up to body temperature before the infusion to avoid unnecessary cooling of the patient.

Ulrik Krogh Andersen (CEO) commented,“prehospital fluid resuscitation before arriving at a hospital is shown to significantly reduce mortality among severely injured patientsWe are thankful that Norwegian National Air Ambulance Services chose our ˚M Warmer System to treat their patients, so we accelerate our mission to improve the survival and recovery rate of patients in critical situations.”

Peter Skade (GLOBAL SALES DIRECTOR) commented, “winning this tender is a confirmation that ˚M Warmer System is a superior solution as it is easy to set up and use and has efficient and powerful warming capacity. The ˚M Warmer System is now adopted by leading HEMS throughout the Nordic countries, UK, mainland Europe and Australia.”

The ˚M Warmer System was awarded the Red Dot Design Award in 2018 for its minimalist expression, user-friendliness, and intuitive design that together reduce the risk of human errors and delays. ˚M Warmer is currently used both in pre-hospital and in-hospital settings, and ˚MEQU is continuously developing its technology to bring warm blood and IV fluids to more patients.

SourceMEQU

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”